"Topotecan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.
Concept/Terms
Topotecan- Topotecan
- 9-Dimethylaminomethyl-10-hydroxycamptothecin
- 9 Dimethylaminomethyl 10 hydroxycamptothecin
- Hycamtamine
Topotecan Hydrochloride- Topotecan Hydrochloride
- Hydrochloride, Topotecan
- Topotecan Monohydrochloride, (S)-Isomer
- Nogitecan Hydrochloride
- Hydrochloride, Nogitecan
SK&F-104864-A- SK&F-104864-A
- SK&F 104864 A
- SK&F104864A
- SKF-104864-A
- SKF 104864 A
- SKF104864A
Hycamtin- Hycamtin
- SmithKline Beecham Brand of Topotecan Hydrochloride
Below are MeSH descriptors whose meaning is more general than "Topotecan".
Below are MeSH descriptors whose meaning is more specific than "Topotecan".
This graph shows the total number of publications written about "Topotecan" by people in Harvard Catalyst Profiles by year, and whether "Topotecan" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 1 | 1 |
1996 | 0 | 3 | 3 |
1997 | 1 | 1 | 2 |
1998 | 2 | 0 | 2 |
1999 | 1 | 3 | 4 |
2000 | 1 | 4 | 5 |
2001 | 3 | 3 | 6 |
2002 | 0 | 3 | 3 |
2003 | 0 | 2 | 2 |
2004 | 2 | 4 | 6 |
2005 | 2 | 3 | 5 |
2006 | 4 | 1 | 5 |
2007 | 3 | 0 | 3 |
2008 | 1 | 3 | 4 |
2009 | 1 | 2 | 3 |
2010 | 2 | 1 | 3 |
2011 | 1 | 2 | 3 |
2012 | 1 | 1 | 2 |
2013 | 2 | 3 | 5 |
2014 | 0 | 3 | 3 |
2015 | 0 | 4 | 4 |
2016 | 0 | 1 | 1 |
2017 | 2 | 4 | 6 |
2018 | 0 | 1 | 1 |
2019 | 0 | 3 | 3 |
2020 | 0 | 2 | 2 |
2021 | 1 | 0 | 1 |
2022 | 0 | 1 | 1 |
2023 | 3 | 0 | 3 |
Below are the most recent publications written about "Topotecan" by people in Profiles.
-
FF-10850, a Novel Liposomal Topotecan Achieves Superior Antitumor Activity via Macrophage- and Ammonia-Mediated Payload Release in the Tumor Microenvironment. Mol Cancer Ther. 2023 Dec 01; 22(12):1454-1464.
-
Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial-mesenchymal Transition in Aggressive Variant Prostate Cancers. Cancer Res Commun. 2023 07; 3(7):1286-1311.
-
Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study. Gynecol Oncol. 2023 04; 171:141-150.
-
Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial. Lancet Oncol. 2022 11; 23(11):1409-1418.
-
Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report. J Clin Oncol. 2021 12 20; 39(36):4029-4038.
-
Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma. Mol Cancer Ther. 2021 08; 20(8):1400-1411.
-
A rational targeted therapy for platinum-resistant small-cell lung cancer. Cancer Cell. 2021 04 12; 39(4):453-456.
-
Synthetic lethal targeting of TET2-mutant hematopoietic stem and progenitor cells (HSPCs) with TOP1-targeted drugs and PARP1 inhibitors. Leukemia. 2020 11; 34(11):2992-3006.
-
Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. Int J Gynecol Cancer. 2020 05; 30(5):596-601.
-
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. Clin Cancer Res. 2020 03 01; 26(5):1009-1016.